Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL80620 | 0.76 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL6304043 | 0.74 | SMN1; SMN2 (0.36) | SMN1; SMN2 | |
| SCHEMBL2080511 | 0.70 | — | — | |
| SCHEMBL22559989 | 0.70 | SMN1; SMN2 (0.33) | SMN1; SMN2 | |
| SCHEMBL1338593 | 0.69 | — | — | |
| SCHEMBL7637281 | 0.68 | SMN1; SMN2 (0.32) | SMN1; SMN2 | |
| SCHEMBL25417178 | 0.65 | — | — | |
| SCHEMBL23462764 | 0.65 | — | — | |
| SCHEMBL7957203 | 0.64 | POLB (0.30) | — | |
| SCHEMBL19838970 | 0.63 | CRBN (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232288-A1 | TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2012-09-13 | — | — | US | disclosed |
| EP-2463274-A1 | Tri-or tetra-substituted-3-aminopyrrolidine deritatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-06-13 | — | — | EP | disclosed |
| US-20100234410-A1 | HYDRATE FOR MEDICAL PURPOSES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-1930321-A1 | PROCESS FOR PREPARATION OF TETRASUBSTITUTED 5-AZASPIRO[2.4]- HEPTANE DERIVATIVES AND OPTICALLY ACTIVE INTERMEDIATES THEREOF | Daiichi Sankyo Company, Limited (JP) | 2008-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232288-A1 | TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE | TLR5, TEAD4, NAALAD2 | SMN1; SMN2 4709/4885 |
| US-20100234410-A1 | HYDRATE FOR MEDICAL PURPOSES | HTR7, UGT1A7, H1-5 | SMN1; SMN2 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.